Tests a new brain delivery method for AB-1005 in people with Parkinson disease

Trial details

Who runs it

AskBio Inc

Trial code

NCT07215403

Record updated

29 October 2026

Original description

This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment.Read full original descriptionShow less

Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment.

Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring.

Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI.

Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT.

Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery

Inclusion: Participant must be 45 to 75 years of age inclusive, at the time of signing the informed consent; >10 years since diagnosis of PD (at time of consenting / Screening Visit 1); Presence of bradykinesia plus any of the following:; Rigidity; Resting tremor; Postural instability; Modified Hoehn and Yahr stage III-IV in the practically defined OFF state; Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score >40 in the practically defined OFF state; Stable anti-PD medication regimen for at least 4 weeks prior to Screening Visit 1 and through Baseline Visit; ≥30% reduction in MDS-UPDRS Part III following a levodopa challenge; Must agree to use barrier method protection when engaging in intercourse/sexual activity with another person for at least 3 months post-dosing; Male participants must refrain from donating sperm for at least 3 months post-dosing; Female participants cannot be pregnant or breastfeeding at the time of screening. A woman of childbearing potential (WOCBP) must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) at the required assessments; Provision of signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol; Provision of signed consent to also participate in LTFU study ASK-PD0-CS002.

Exclusion: Presence or history (within 2 years prior to screening) of substance use disorder (including alcohol) as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria (or in the judgment of the neurologist); Stroke, transient ischemic attack, or other suspected cerebrovascular accident within 1 year prior to screening; Unstable angina pectoris or myocardial infarction within 1 year prior to screening; Revascularization procedure(s) within 1 year prior to screening; Inability to identify a safe trajectory to each putamen via an occipitoparietal entry point, or known contraindications to brain surgery in prone position (as determined by the neurosurgeon); Concurrent use of percutaneous levodopa/carbidopa intestinal gel, subcutaneous levodopa, or apomorphine pump; Chronic immunosuppressive therapy; History of prior cell or gene therapy; Participation in other interventional clinical trials within 12 weeks prior to screening or unwilling to refrain from starting new investigational agents throughout the course of the study; Unwilling to defer any vaccination from screening through 1 month after surgery; Presence or history of psychosis or impulse control disorder (as determined by the neurologist); Current suicidal ideation as indicated by positive response to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C SSRS), or any history of a suicide attempt; Clinically significant cognitive impairment (Montreal Cognitive Assessment [MoCA] score <25); Presence or history of malignancy other than treated cutaneous squamous or basal cell carcinomas; Presence of clinically active infection, including acute or chronic scalp infection; Presence or history of significant cerebrovascular or cardiovascular disease, including:; Poorly controlled hypertension, poorly controlled diabetes mellitus or prediabetes mellitus with known significant microvascular injury, or other significant cardiovascular history or risk factor; Known history of complications of anesthesia including difficult airway management and/or difficult endotracheal intubation, malignant hyperthermia, or other related issues that would compromise participant safety during general anesthesia (as determined by the anesthesiologist); Known allergy or sensitivity to ingredients in the intervention formulation and/or to gadolinium-based contrast agents; History of brain surgery (including deep brain stimulation [DBS] or focused ultrasound); Laboratory values at screening:; Platelets ≤100,000/mm3; PT >15 s, aPTT >40 s, and/or INR >1.3; Absolute neutrophil count (ANC) ≤1500/mm3; Hemoglobin ≤10.0 g/dL; Total bilirubin ≥2.5 mg/dL; eGFR <45 mL/min/1.73 m2; HbA1C ≥8%; Evidence of secondary or atypical parkinsonism (as determined by the neurologist); Presence of untreated or sub optimally treated depression (Beck Depression Inventory [BDI]-II score ≥20); Known contraindications to MRI; Aspartate aminotransferase or alanine aminotransferase ≥2.5 times the upper limit of normal; Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments (during LTFU study ASK-PD0-CS002); Any significant issue raised by the neurologist, neurosurgeon, or anesthesiologist that may make a participant unsuitable for the study.

ClinicalTrials.gov NCT07215403